- Home
- SNGX vs EVAX Comparison
SNGX vs EVAX Comparison
Compare SNGX & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNGX
- EVAX
- Stock Information
- Founded
- SNGX 1987
- EVAX 2008
- Country
- SNGX United States
- EVAX Denmark
- Employees
- SNGX N/A
- EVAX N/A
- Industry
- SNGX Biotechnology: Pharmaceutical Preparations
- EVAX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SNGX Health Care
- EVAX Health Care
- Exchange
- SNGX Nasdaq
- EVAX Nasdaq
- Market Cap
- SNGX 6.5M
- EVAX 15.1M
- IPO Year
- SNGX 1987
- EVAX 2021
- Fundamental
- Price
- SNGX $1.27
- EVAX $2.54
- Analyst Decision
- SNGX
- EVAX Strong Buy
- Analyst Count
- SNGX 0
- EVAX 2
- Target Price
- SNGX N/A
- EVAX $10.00
- AVG Volume (30 Days)
- SNGX 2.7M
- EVAX 102.6K
- Earning Date
- SNGX 08-08-2025
- EVAX 08-13-2025
- Dividend Yield
- SNGX N/A
- EVAX N/A
- EPS Growth
- SNGX N/A
- EVAX N/A
- EPS
- SNGX N/A
- EVAX N/A
- Revenue
- SNGX $2,342.00
- EVAX $3,293,000.00
- Revenue This Year
- SNGX N/A
- EVAX N/A
- Revenue Next Year
- SNGX N/A
- EVAX N/A
- P/E Ratio
- SNGX N/A
- EVAX N/A
- Revenue Growth
- SNGX N/A
- EVAX 2555.64
- 52 Week Low
- SNGX $1.09
- EVAX $1.20
- 52 Week High
- SNGX $7.61
- EVAX $17.75
- Technical
- Relative Strength Index (RSI)
- SNGX 38.93
- EVAX 58.32
- Support Level
- SNGX $1.24
- EVAX $2.26
- Resistance Level
- SNGX $1.38
- EVAX $2.85
- Average True Range (ATR)
- SNGX 0.14
- EVAX 0.22
- MACD
- SNGX 0.01
- EVAX 0.01
- Stochastic Oscillator
- SNGX 27.22
- EVAX 59.45
About SNGX Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).
About EVAX Evaxion Biotech
Evaxion AS is in the field of oncology. It used the AI-Immunology platform.